Updates are available Correction dated 2024-12-12
Click to view Correction: https://doi.org/10.1038/s41592-024-02578-y
-
Authors
Seal, Srijit https://orcid.org/0000-0003-2790-8679
Trapotsi, Maria-Anna https://orcid.org/0000-0002-9177-4241
Spjuth, Ola https://orcid.org/0000-0002-8083-2864
Singh, Shantanu https://orcid.org/0000-0003-3150-3025
Carreras-Puigvert, Jordi
Greene, Nigel
Bender, Andreas https://orcid.org/0000-0002-6683-7546
Carpenter, Anne E. https://orcid.org/0000-0003-1555-8261
- License Information
-
More Information
Article History
Received: 11 April 2024
Accepted: 24 September 2024
First Online: 5 December 2024
Change Date: 12 December 2024
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41592-024-02578-y
Competing interests
: S. Singh and A.E.C. serve as scientific advisors for companies that use image-based profiling and Cell Painting (A.E.C.: Recursion, SyzOnc, Quiver Bioscience; S. Singh: Waypoint Bio, Dewpoint Therapeutics, DeepCell) and receive honoraria for occasional talks at pharmaceutical and biotechnology companies. J.C.P. and O.S. declare ownership in Phenaros Pharmaceuticals. M.-A.T. and N.G. were formerly employed at AstraZeneca. M.-A.T. and N.G. are currently employed at Recursion Pharmaceuticals. The remaining authors declare no competing interests.
